Muscle Loss

Astaxanthin and Sarcopenia (Muscle Loss)

Dr. Irwin Rosenberg coined the term ‘sarcopenia’ in 1988, which was instrumental in highlighting a pathological condition that has serious consequences to individuals and society.   Sarcopenia is the progressive loss of muscle mass or quality characterized by a decline in muscle strength and/or performance.

Sarcopenia has a significant clinical impact, and affects a patient’s quality of life as a result of a decline in mobility and independence.  Most people begin to lose muscle mass and function after the age of 30.  However, the resulting loss of muscle strength increases exponentially with age.  Recent estimates indicate that approximately 45% of the older U.S. population is affected by sarcopenia.

While the causes and mechanisms of sarcopenia are not completely resolved, inadequate nutrition and physical inactivity are known to influence the metabolic imbalance of proteins in skeletal muscle.  Moreover, elevated levels of reactive oxygen species (ROS) and chronic inflammation during aging make it more difficult to meet adequate dietary and nutritional needs.

In addition to diet and exercise, scientific literature suggests that antioxidants may be helpful in the management of sarcopenia.  The use of antioxidants to reduce ROS levels has been widely advocated. The importance of the properties and activities of an antioxidant in the management of sarcopenia is the reason Astaxanthin may play an integral role in combating sarcopenia.  

The powerful antioxidant and anti-inflammatory capabilities of Astaxanthin reduce ROS levels, decrease chronic inflammation, and can have a direct and positive effect on protein synthesis and mitochondrial oxidation. This is especially important in addressing the multifactorial etiology of sarcopenia.

 

References

  1. Brotto M. Lessons from the FNIH-NIA-FDA sarcopenia consensus summit. IBMS Bonekey. 2012 Nov; 9: 210.
  2. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The Healthcare Costs of Sarcopenia in the United States. Journal of the American Geriatric Society 52:80?85, 2004.
  3. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis. Age Ageing. 2010 Jul; 39(4): 412-23.
  4. Peterson CM, Johannsen DL, Ravussin E. Skeletal muscle mitochondria and aging: a review. J Aging Res. 2012; 194821.
  5. Jackson MJ. Strategies for reducing oxidative damage in ageing skeletal muscle. Adv Drug Deliv Rev. 2009 Nov; 61(14): 1363-8.

 

Please contact us for more details on how natural Astaxanthin can help patients with muscle loss.